Status:
COMPLETED
Cardiac Electrophysiological Study
Lead Sponsor:
AstraZeneca
Conditions:
Atrial Flutter
Eligibility:
All Genders
20-80 years
Phase:
PHASE2
Brief Summary
The purpose of the study is to measure the effects of AZD1305 on cardiac electrophysiological properties and intracardiac pressures
Eligibility Criteria
Inclusion
- Patients with atrial flutter (with a ventricular rate of \<100 beats/minute at enrolment), scheduled for curative catheter ablation
- Sinus rhythm at randomisation
Exclusion
- QTc (Fridericia, QTcF ) \>450 ms measured in sinus rhythm at randomisation,
- Serum potassium below 3.8 or above 5.0 mmol/L or plasma potassium below 3.6 or above 5.0 mmol/L
- QRS duration \>120 ms at randomisation
Key Trial Info
Start Date :
January 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2008
Estimated Enrollment :
55 Patients enrolled
Trial Details
Trial ID
NCT00616629
Start Date
January 1 2008
End Date
June 1 2008
Last Update
September 22 2011
Active Locations (13)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Aalborg, Denmark
2
Research Site
Aarhus, Denmark
3
Research Site
Copenhagen, Denmark
4
Research Site
Hellerup, Denmark